RO6889450 + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia, Schizoaffective Disorder
Conditions
Schizophrenia, Schizoaffective Disorder
Trial Timeline
Dec 4, 2018 → Mar 12, 2023
NCT ID
NCT03669640About RO6889450 + Placebo
RO6889450 + Placebo is a phase 2 stage product being developed by Roche for Schizophrenia, Schizoaffective Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT03669640. Target conditions include Schizophrenia, Schizoaffective Disorder.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia, Schizoaffective Disorder were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03669640 | Phase 2 | Terminated |
Competing Products
20 competing products in Schizophrenia, Schizoaffective Disorder